BillionToOne reported a 64% year-over-year revenue increase for the second quarter of 2026, reaching $109.4 million and achieving GAAP profitability. Results were driven by a 35% increase in test volumes and significant expansion in the oncology segment, allowing the company to reiterate its full-year 2026 revenue guidance.
Key Highlights
- Total revenue reached $109.4 million, supported by a 55% increase in prenatal testing and 176% growth in oncology clinical testing revenue.
- Gross profit margin expanded 500 basis points to 70%, fueled by a 21% improvement in overall Average Selling Price (ASP) to $551.
- Operating income turned positive at $5.5 million compared to a $1.6 million loss in the prior-year period, representing a 5% operating margin.